<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599429</url>
  </required_header>
  <id_info>
    <org_study_id>CIMS-2011-01</org_study_id>
    <nct_id>NCT01599429</nct_id>
  </id_info>
  <brief_title>Study of the Predictive Marker FLT in Patients Suffering From AML</brief_title>
  <acronym>TEP-FLT-LMA</acronym>
  <official_title>Use of FLT-TEP Scan as Predictive Marker and Early Prognostic in Patients Suffering From AML Treated by Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Positron emission tomography uses various radioactive tracers to measure the metabolic&#xD;
      activity in a none-invasive way, and specially to follow the activity of the disease during&#xD;
      the treatments.&#xD;
&#xD;
      Among those new tracers, fluorothymidine (18F-FLT) arouses a lot of interest. This new tool&#xD;
      would allow to image and follow time wise acute myeloid leukemia (AML). The investigators&#xD;
      want, with the (18F-FLT), to characterise the aggressivity of the tumors and the prognostic&#xD;
      before and after chemotherapy treatment.&#xD;
&#xD;
      The aim of this study is to be able to identify earlier the responders, because if they are&#xD;
      detected sooner, these patients will benefit from more aggressive treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled&#xD;
  </why_stopped>
  <start_date>October 31, 2011</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To mesure the pronostic value of metabolic activity in the bone marrow with FLT-PET prior to chemotherapy in patients with AML disease.</measure>
    <time_frame>September 2015</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients newly diagnosed with acute myeloid, between October 2011 and October 2013, at the&#xD;
        Centre Hospitalier Universitaire de Sherbrooke (CHUS).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients 18 years or above at the time of inclusion;&#xD;
&#xD;
          2. Patients newly diagnosed with acute myeloid leukemia;&#xD;
&#xD;
          3. No contraindication or intolerance to any of the components of the standard&#xD;
             chemotherapy by induction (7+3);&#xD;
&#xD;
          4. Patients able to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients unable to tolerate decubitus position for at least 45 minutes;&#xD;
&#xD;
          2. Any previous neoplasia or other neoplasia simultaneously;&#xD;
&#xD;
          3. Previously treated buy radiotherapy, with bone marrow in the field of radiation;&#xD;
&#xD;
          4. Other chemotherapy treatment than the standard chemotherapy by induction (7+3), before&#xD;
             the second FLT-TEP was done.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Éric E Turcotte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Centre d'imagerie moléculaire de Sherbrooke (CIMS), Centre de recherche Étienne Le-Bel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rami Kotb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2012</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre de recherche du Centre hospitalier universitaire de Sherbrooke</investigator_affiliation>
    <investigator_full_name>Dr Éric E Turcotte, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>AML / LMA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

